Defining patient risks from expanded preventive therapies.
about
Statins and its hepatic effects: Newer data, implications, and changing recommendationsNon-cardiovascular effects associated with statinsRhabdomyolysis with concurrent atorvastatin and diltiazemLooking beyond highly active antiretroviral therapy: drug-related hepatotoxicity in patients with human immunodeficiency virus infection.The toxicology of HMG-CoA reductase inhibitors: prediction of human risk.Statin Hepatotoxicity: Is it a Real Concern?Lipid-lowering agents that cause drug-induced hepatotoxicity.Idiosyncratic drug hepatotoxicity.Drug-Induced Liver Injury: Pattern Recognition and Future Directions.The safety of rosuvastatin: effects on renal and hepatic function.The role of statin drugs in the management of the peripheral vascular patient.Fenofibrate does not affect burn-induced hepatic endoplasmic reticulum stressMedical Care of the Patient With Compensated Cirrhosis.The myth of statin-induced hepatotoxicity.In silico models for drug-induced liver injury--current status.Long-term outcome after liver transplantation.Clinical perspective: statins and the liver--harmful or helpful?Towards companion diagnostics for the management of statin therapy.Pilot Algorithm Designed to Help Early Detection of HMG-CoA Reductase Inhibitor-Induced Hepatotoxicity.
P2860
Q26767065-16249D43-E474-492F-9AF2-67F6C8562CF2Q27026332-C0C5C48F-BE0D-4BCA-B764-E6CE459DA3FDQ28193807-FC21C993-0F0F-4325-ABAC-10E5BCEF6244Q34998102-116C4D94-A077-41DF-88FC-6EF9974C25BBQ35927194-B3E5C379-D5A4-46C3-81F8-FDD99B0BD264Q35936329-34639469-084A-4AF4-AEA9-C594773A400BQ36103339-ECABB047-D1E7-4240-A6B4-53D47EF51429Q36148442-55C06343-0B42-45C0-82DA-112FDCFFD495Q36412863-A986ABEA-D8EF-4E4A-9A7F-929A65E72570Q36945023-386A6281-C6F5-47D8-BE16-646B4640A5DCQ37214238-EAB0D823-33E1-4D13-A0E9-52A89D2063D2Q37297015-65E9C3D4-F7AD-4BC5-A48E-FD827AC015B1Q37678908-77850B68-AAF6-429D-AFD0-3CABEDAC2419Q37743155-8D33425A-DC5F-4A7B-83F7-F8382692935AQ37976120-30DE26FA-EAC9-4F1A-9846-735C54308DDCQ38002368-068E41A8-B214-474B-9828-745A6A198BB1Q38009719-6EC67C0C-4E89-425E-BE12-226CA8AFC802Q38089842-4A69393E-2D80-4340-A933-7100E14F2001Q41528115-36AFB40B-0831-482C-9CE3-A24FDA2B3F34
P2860
Defining patient risks from expanded preventive therapies.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
name
Defining patient risks from expanded preventive therapies.
@ast
Defining patient risks from expanded preventive therapies.
@en
type
label
Defining patient risks from expanded preventive therapies.
@ast
Defining patient risks from expanded preventive therapies.
@en
prefLabel
Defining patient risks from expanded preventive therapies.
@ast
Defining patient risks from expanded preventive therapies.
@en
P1476
Defining patient risks from expanded preventive therapies.
@en
P2093
K G Tolman
P304
P356
10.1016/S0002-9149(00)00946-2
P407
P577
2000-06-01T00:00:00Z